Shots:

• The European Commission has granted marketing authorization for Rhokiinsa 0.02% for reducing the elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension
• The EC’s approval demonstrated the potential value of Aerie’s netarsudil franchise at an international level.  The EC has accepted its MAA in Oct’2018 and it has received CHMP’s positive opinion in Sept’2019
• Rhokiinsa (marketed as Rhopressa 0.02% in the US ) is once-daily eye drop approved by the US FDA for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension- was launched in the US in April' 2018. Aerie plans to file MAA for its Roclanda in H1’20

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Aerie Pharmaceuticals